Mani Foroohar
Stock Analyst at Leerink Partners
(2.65)
# 2,216
Out of 5,072 analysts
172
Total ratings
51.58%
Success rate
1.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mani Foroohar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNA Moderna | Maintains: Underperform | $15 → $18 | $24.75 | -27.27% | 19 | Nov 21, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Outperform | $9 → $20 | $9.72 | +105.76% | 6 | Oct 7, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Market Perform | $9 → $7 | $3.10 | +125.81% | 13 | Oct 3, 2025 | |
| SRPT Sarepta Therapeutics | Downgrades: Market Perform | $45 → $10 | $19.35 | -48.32% | 2 | Jul 21, 2025 | |
| RXRX Recursion Pharmaceuticals | Maintains: Market Perform | $7 → $6 | $4.37 | +37.30% | 8 | Feb 28, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $31 → $27 | $10.68 | +152.81% | 9 | Jan 13, 2025 | |
| NGNE Neurogene | Maintains: Outperform | $45 → $72 | $20.69 | +247.99% | 2 | Nov 12, 2024 | |
| CAMP Camp4 Therapeutics | Initiates: Outperform | $17 | $3.38 | +402.96% | 1 | Nov 5, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $47 → $49 | $71.76 | -31.72% | 11 | Oct 17, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $47 → $46 | $70.63 | -34.87% | 15 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $22 | $7.43 | +196.10% | 6 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $53 → $62 | $80.93 | -23.39% | 15 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $12.93 | +0.54% | 1 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $17.45 | +66.19% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $12 → $4 | $5.28 | -24.24% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $13.45 | - | 10 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $7.71 | +302.08% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.23 | +469.11% | 1 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $40 | $46.79 | -14.51% | 12 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $86 → $84 | $8.55 | +882.46% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $6 → $7 | $2.39 | +192.89% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $77 | $24.69 | +211.87% | 2 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $144 → $143 | $429.80 | -66.73% | 11 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $6 | $4.88 | +22.95% | 5 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $76 | $53.57 | +41.87% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $1.87 | +1,718.18% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $50 → $20 | $4.09 | +389.00% | 6 | Jul 23, 2021 |
Moderna
Nov 21, 2025
Maintains: Underperform
Price Target: $15 → $18
Current: $24.75
Upside: -27.27%
Lexeo Therapeutics
Oct 7, 2025
Maintains: Outperform
Price Target: $9 → $20
Current: $9.72
Upside: +105.76%
Rocket Pharmaceuticals
Oct 3, 2025
Maintains: Market Perform
Price Target: $9 → $7
Current: $3.10
Upside: +125.81%
Sarepta Therapeutics
Jul 21, 2025
Downgrades: Market Perform
Price Target: $45 → $10
Current: $19.35
Upside: -48.32%
Recursion Pharmaceuticals
Feb 28, 2025
Maintains: Market Perform
Price Target: $7 → $6
Current: $4.37
Upside: +37.30%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Outperform
Price Target: $31 → $27
Current: $10.68
Upside: +152.81%
Neurogene
Nov 12, 2024
Maintains: Outperform
Price Target: $45 → $72
Current: $20.69
Upside: +247.99%
Camp4 Therapeutics
Nov 5, 2024
Initiates: Outperform
Price Target: $17
Current: $3.38
Upside: +402.96%
Mirum Pharmaceuticals
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $49
Current: $71.76
Upside: -31.72%
BridgeBio Pharma
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $46
Current: $70.63
Upside: -34.87%
Oct 16, 2024
Maintains: Outperform
Price Target: $20 → $22
Current: $7.43
Upside: +196.10%
Jul 24, 2024
Upgrades: Outperform
Price Target: $53 → $62
Current: $80.93
Upside: -23.39%
Jul 22, 2024
Initiates: Outperform
Price Target: $13
Current: $12.93
Upside: +0.54%
Jul 2, 2024
Initiates: Outperform
Price Target: $29
Current: $17.45
Upside: +66.19%
Apr 25, 2024
Downgrades: Market Perform
Price Target: $12 → $4
Current: $5.28
Upside: -24.24%
Mar 6, 2024
Upgrades: Outperform
Price Target: n/a
Current: $13.45
Upside: -
Feb 20, 2024
Initiates: Outperform
Price Target: $31
Current: $7.71
Upside: +302.08%
Nov 30, 2023
Initiates: Outperform
Price Target: $7
Current: $1.23
Upside: +469.11%
May 12, 2023
Downgrades: Market Perform
Price Target: $40
Current: $46.79
Upside: -14.51%
Jan 23, 2023
Maintains: Outperform
Price Target: $86 → $84
Current: $8.55
Upside: +882.46%
Jan 23, 2023
Maintains: Market Perform
Price Target: $6 → $7
Current: $2.39
Upside: +192.89%
Jan 23, 2023
Maintains: Outperform
Price Target: $81 → $77
Current: $24.69
Upside: +211.87%
Jan 23, 2023
Maintains: Market Perform
Price Target: $144 → $143
Current: $429.80
Upside: -66.73%
Nov 14, 2022
Maintains: Market Perform
Price Target: $5 → $6
Current: $4.88
Upside: +22.95%
Nov 7, 2022
Maintains: Outperform
Price Target: $75 → $76
Current: $53.57
Upside: +41.87%
May 12, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $1.87
Upside: +1,718.18%
Jul 23, 2021
Maintains: Market Perform
Price Target: $50 → $20
Current: $4.09
Upside: +389.00%